Clinical Trial Update: Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity trial updating results for revaccination with BCG, H4:IC31, and H56:IC31 in healthy adolescents for tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• H4:IC31
• H56:IC31

Snippet

Sponsor: Aeras | Conditions: Tuberculosis | Phase 1 | Status: COMPLETED | Results posted: 2019-11-18